SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense bullish momentum as investors re-rate the company from a cyclical manufacturer to a foundational player in the AI infrastructure supercycle, driven by persistent supply shortages and explosive demand for high-bandwidth memory. While the community is actively debating the sustainability of this parabolic move, much of the discourse focuses on supply constraints, long-term earnings potential, and the divergence between current valuations and the massive scaling of AI data centers.

Aventus Network

Aventus Network is currently trending as the community highlights its low market capitalization, Polkadot integration, and recent strategic advisory appointments in the UAE as potential catalysts for a breakout. Traders are actively debating its enterprise-grade utility, with many expressing interest in its long-term potential while closely monitoring trading volume for signs of a sustained move.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is seeing significant market momentum driven by a strong quarterly earnings report that highlighted the expansion of its Matrix-M adjuvant technology into over 30 oncology and infectious disease fields. While community sentiment is divided between optimism over potential strategic partnerships and frustration regarding executive compensation, shares are rallying as traders speculate on the firm's role in the vaccine landscape and potential future buyouts.

Rackspace Technology, Inc. engages in the provision of end-to-end multi-cloud technology services. The firm designs, builds and operates its customers’ cloud environments across technology platforms. It operates through the following segments: Multicloud Services and Apps & Cross Platform. The Multicloud Services segment includes public and private cloud managed services offerings, as well as professional services related to designing and building multicloud solutions and cloud-native applications. The Apps & Cross Platform segment includes managed applications, managed security and data services, as well as professional services related to designing and implementing application, security and data services. The company was founded on July 21, 2016 and is headquartered in San Antonio, TX.

Rackspace Technology Inc

Rackspace Technology is trending due to a combination of Q1 profitability and a new memorandum of understanding with AMD to develop enterprise AI infrastructure, triggering a significant rally and active short-squeeze speculation. Community discussions are split between bulls betting on a major AI-driven turnaround and bears warning of potential equity dilution to manage the company's substantial debt load.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant market interest driven by ongoing momentum in its mRNA oncology platform and promising clinical data from its flu and combination vaccine programs, which are currently being presented at major industry events. The community remains focused on the company's efforts to expand beyond COVID-19, with active discussions surrounding potential clinical readouts, institutional accumulation, and the stock's position as a high-beta biotech play with strong short-interest dynamics.

NovaChargeX Coin (NCX) is an Ethereum-based ERC-20 token connected to NovaChargeX LLC, a clean-energy company developing patented hybrid regenerative power systems designed to deliver continuous, grid-independent electricity. The token serves as the on-chain entry point to the NovaChargeX ecosystem, linking blockchain participants to a real-world infrastructure project focused on supplying 24/7 power to AI data centers, industrial facilities, and other operations that cannot tolerate downtime. NCX is positioned in the real-world asset (RWA) and clean-energy infrastructure category. The parent company has been recognized by the World Future Awards 2025 for Best Hybrid Regenerative Clean Energy System and has received coverage from Al Arabiya English, SolarQuarter, and Reuters. The token contract is deployed on Ethereum mainnet, ownership has been renounced, and a third-party security audit has been completed.

NovaChargeX Coin

NovaChargeX is capturing investor interest as market participants highlight its integration of clean energy infrastructure with blockchain and AI power demand. The community is actively discussing the project's real-world utility and emerging real-world asset narrative as a potential alternative to speculative meme tokens.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

Investors are actively debating the Fundrise Innovation Fund's massive premium over its net asset value, with some seeing the exposure to high-profile private AI and tech companies as a generational opportunity while others warn of significant downside risk from insider share sales. Community sentiment is deeply divided, as traders oscillate between celebrating the ticker's explosive volatility and expressing frustration over the lack of transparency and speculative price swings.

Julong Holding Ltd. engages in the business of investment holding activities. It provides intelligent integrated solutions to public utilities, enterprises, commercial, and multifamily properties. The company was founded by Jia Qi Hu on August 07, 2023 and is headquartered in Beijing, China.

Julong Holding Ltd. - Ordinary Shares - Class A

Julong Holding Ltd. ($JLHL) is trending as retail investors circulate comparisons to previous low-float Chinese stocks that experienced parabolic rallies, fueling speculation that this ticker may see a similar short squeeze. The community is focused on the stock's extremely thin effective float and high insider ownership, with traders actively monitoring level 2 data and volatility pauses in hopes of a rapid upward move.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is drawing significant investor interest as a primary proxy for pre-IPO exposure to high-profile companies like SpaceX and Anthropic. Community discussion is focused on the fund's potential Net Asset Value upside, the anticipation surrounding upcoming IPO timelines, and debate over its valuation premium compared to broader market alternatives.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is trending as retail and institutional investors pile into the stock, driven by a narrative that its specialized MRAM memory technology is essential for the future of edge AI and space-hardened infrastructure. The community is actively discussing its potential for a massive short squeeze due to its low float and perceived sympathy with broader semiconductor and memory market momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lifecore Biomedical (NASDAQ:LFCR) Posts Quarterly Earnings Results, Misses Expectations By $0.19 EPS

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.19). Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of...

Lifecore Biomedical Q1 Earnings Call Highlights

Lifecore Biomedical (NASDAQ:LFCR) executives highlighted new commercial site transfer wins, continued cost reductions, and improving liquidity during the company's first-quarter 2026 earnings call...

Lifecore Biomedical Q1 2026 Earnings Call Transcript

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Given Average Recommendation of "Hold" by Brokerages

Lifecore Biomedical, Inc. (NASDAQ:LFCR - Get Free Report) has been assigned a consensus recommendation of 'Hold' from the five brokerages that are currently covering the company, Marketbeat.com...

Lifecore Biomedical (NASDAQ:LFCR) Price Target Raised to $6.00

Barrington Research upped their target price on Lifecore Biomedical from $5.50 to $6.00 and gave the stock an "outperform" rating in a research note on Wednesday...

Lifecore Biomedical (LFCR) to Release Earnings on Tuesday

Lifecore Biomedical (NASDAQ:LFCR) will be releasing earnings after the market closes on Tuesday, May 5. (View Earnings Report at...

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Receives Average Recommendation of "Hold" from Analysts

Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR - Get Free Report) have received a consensus recommendation of "Hold" from the five brokerages that are covering the firm, MarketBeat reports. One...

Lifecore Biomedical (LFCR) to Release Earnings on Thursday

Lifecore Biomedical (NASDAQ:LFCR) will be releasing earnings after the market closes on Thursday, April 2. (View Earnings Report at...

Lifecore Biomedical (NASDAQ:LFCR) Earns Outperform Rating from Barrington Research

Barrington Research reiterated an "outperform" rating and issued a $5.50 price target on shares of Lifecore Biomedical in a research report on Tuesday...

Lifecore Biomedical CEO: Standalone CDMO Shift Complete, Utilization to Hit 60% by 2029

Lifecore Biomedical (NASDAQ:LFCR) CEO Paul Josephs told investors at a KeyBanc conference that the company has completed its transition into a standalone CDMO after divesting its former food...

Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. It focuses on selling products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, and non-HA products for medical use primarily in the Ophthalmic, Orthopedic and other markets. The company was founded by Otto Sartorius in 1965 and is headquartered in Chaska, MN.

Lifecore Biomedical Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

LFCR
Lifecore Biomedical Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest LFCR News

LFCRLifecore Biomedical Inc